Sculptra

No — Sculptra’s main microparticle material is poly-L-lactic acid (PLLA), not hyaluronic acid. The U.S. instructions for use describe it as a sterile injectable implant placed in deeper tissue, with correction that develops gradually rather than on the treatment day.

Different materials: Sculptra is PLLA-based, HA filler is a hyaluronic-acid gel. The U.S. label for Sculptra covers nasolabial folds, other facial wrinkles and cheek lines, with change appearing gradually over several weeks and often across a planned series. Hyaluronic-acid products sit in a separate material category on the FDA’s approved dermal filler list and are chosen when an immediate, gel-based filling effect is the goal. Bring the exact area and the kind of change you want to the consultation instead of a brand name.

They answer different goals rather than competing on strength. Sculptra is a PLLA injectable planned as a series in which correction develops gradually; Rejuran is a polynucleotide (PN) injectable that PharmaResearch presents for temporary improvement of facial wrinkles. Confirm the exact product, the tissue layer treated, and the approval that applies in the country where you are treated.

No — "collagen stimulator" is a marketing umbrella, and the base material differs by product. Sculptra’s microparticles are PLLA according to its U.S. labeling, and the FDA’s approved dermal filler list identifies each product by material and approved use, so two products advertised with the same phrase can carry very different labels. Ask for the product name, its material, and the labeling that applies where you are treated.

No — the intended correction develops gradually over several weeks rather than on the treatment day. Early fullness can partly reflect reconstitution fluid and swelling. Ask the clinic what change is expected and when it will be assessed.

No — 24 months is a study follow-up period, not a guaranteed personal duration. A U.S. randomized trial for cheek wrinkles found improvement maintained through a 24-month follow-up compared with no treatment. That describes the study population’s average finding over that period, not a personal guarantee; individual duration varies.

The U.S. instructions for use say up to four sessions may be needed. The exact number and interval depend on the indication and individual assessment, and must follow the labeling that applies where treatment is performed.

Pain, tenderness, swelling, redness and bruising at the injection site are listed as common reactions. Most are described as mild to moderate, and bleeding, itching and lumps are also listed. The product may be reconstituted with lidocaine, so declare any amide local-anesthetic allergy beforehand. Because papules or nodules can appear days to months later, agree on a follow-up route with the clinic before you travel home.

The U.S. IFU says not to inject the lip vermilion and states peri-orbital use has not been studied and has a reported increased risk of papules and nodules. These are two separate statements: one is a labeled prohibition, the other is an unstudied area with a reported risk. Both describe U.S. labeling, so confirm the plan for your area with the treating clinic.

No — papules or nodules may appear days to months after injection and can take time to resolve. Swelling and small lumps can also occur right away as a common early reaction. Report any new or persisting lump to the treating clinic rather than waiting for it to settle on its own.

U.S. labeling rules out several groups, so candidacy is decided by history rather than by age alone. It excludes people hypersensitive to an ingredient and those with a history of severe allergy or anaphylaxis, multiple severe allergies, or keloid or hypertrophic scarring. Treatment is deferred where the area has active inflammation or infection, and safety is not established in pregnancy, breastfeeding or under age 18. The U.S. indication is written for immunocompetent adults, so bring your full allergy, scar, medication and immune history to the consultation.

Sculptra holds a U.S. FDA premarket approval (PMA P030050S039) and appears on the FDA’s approved dermal filler list. That record describes U.S. labeling only; it does not state anything about Korean approval or scope, and this page cannot confirm the Korean status. Ask the clinic which product and labeling it uses domestically, and confirm the injector’s qualification.

This page does not publish prices, so compare quotes by what one session actually includes. Line up the treated area, how many sessions the plan assumes, whether follow-up visits and aftercare are included, and the exact product used. A single headline figure is not comparable between clinics unless those items match.

Only a properly licensed healthcare professional trained in Sculptra’s approved indications and injection requirements should administer it. You can ask who will inject, what training they have, and how vascular complications or delayed nodules would be managed.